News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Guilherme Nader Marta: DESTINY-Breast06 trial out in The New England Journal of Medicine
medimix.be
Sep 19, 2024, 09:29

Guilherme Nader Marta: DESTINY-Breast06 trial out in The New England Journal of Medicine

Guilherme Nader Marta, Advanced Clinical Fellow – Dana-Farber Cancer Institute, shared a post on LinkedIn:

“DESTINY-Breast06 trial out in The New England Journal of Medicine

T-DXd improved median PFS to 13.2 mos vs 8.1 mos w/ chemo (HR 0.62, CI 0.51–0.74) in HR+/HER2-low mBC after 1-2 lines of ET

Consistent results in the HER2-ultralow population (HR 0.78, CI 0.5-1.2)

OS data immature.”

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Authors: Aditya Bardia,  Xichun Hu, Rebecca Dent,  Kan Yonemori, Carlos H. Barrios,  Joyce A. O’Shaughnessy, Hans Wildiers, Jean-Yves Pierga,  Qingyuan Zhang, Cristina Saura,  Laura Biganzoli, Joohyuk Sohn,  Seock-Ah Im, Christelle Lévy, William Jacot,  Natasha Begbie, Jun Ke,  Gargi Patel, and Giuseppe Curigliano.

Guilherme Nader Marta: DESTINY-Breast06 trial out in The New England Journal of Medicine

 

Source: Guilherme Nader Marta/X

Aditya Bardia cancer cancer awareness Carlos H. Barrios Christelle Levy Cristina Saura fight against cancer Gargi Patel Giuseppe Curigliano Global fight against cancer Guilherme Nader Marta Hans Wildiers Jean-Yves Pierga Joohyuk Sohn Joyce A. O’Shaughnessy Jun Ke Kan Yonemori Laura Biganzoli Natasha Begbie OncoDaily Oncology Qingyuan Zhang Rebecca Dent Seock-Ah Im The New England Journal of Medicine. William Jacot Xichun Hu
Special Coverage
Insight
Dec 25, 2024, 03:51
Maria Babak: Critical advancement in the treatment of mCSCC and laCSCC
Science
Dec 25, 2024, 03:40
The effect of exercise in aiding cancer treatment and mitigating the treatment side-effects, suggested by Christopher Fitzmaurice
Blog
Dec 25, 2024, 03:35
Amol Akhade: Use of Dostarlimab plus niraparib in first line Advanced Ovarian Cancer
Insight
Dec 25, 2024, 03:32
Optimising Cancer Care for Older Adults - MASCC
Insight
Dec 25, 2024, 03:00
Mazyar Shadman: Venetoclax - based therapy after cBTKi in CLL led by Nilanjan Ghosh
Insight
Dec 25, 2024, 02:57
Jarushka Naidoo: Important paper on incidence and outcomes of EGFR+ NSCLC
Insight
Dec 25, 2024, 02:41
Correlating PSA Dynamics with Outcomes of Lutetium-177-PSMA-617 Treatment - European Urology
Science
Dec 25, 2024, 02:35
Hospital Participation in the Acute Hospital Care at Home Waiver Program by Hashem Zikry et al.
Science
Dec 25, 2024, 01:52
Erman Akkus: Role of PD-L1 expression in advanced esophageal SCC by Manavi Sachdeva et al.
Blog
Dec 25, 2024, 01:50
Results of SISAQOL-IMI: Advancing Patient-Reported Outcomes Research
Science
Dec 24, 2024, 23:45
Tatiana Prowell: Genomic profiling performed on 822 breast cancer brain metastases by Athina Giannoudis et al.
Blog
Dec 24, 2024, 23:42
Extending the pandemic-era telehealth flexibilities in Medicare - ASCO